Osteogenic Peptide (BMP-mimetic class)
/ Heterogeneous class — synthetic peptides typically 15-30 residues derived from BMP-2 or BMP-7 knuckle-epitope regionsALIAS · BMP-mimetic peptide (generic) · Bone-morphogenetic-protein mimetic peptide
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 3 by class. 'Osteogenic peptide' as sold by vendors is not a single defined molecule — it is a generic label covering small peptides derived from BMP-2, BMP-7, or other bone-morphogenetic-protein knuckle-epitope regions designed to mimic receptor binding without the manufacturing complexity of full recombinant proteins. Specific peptide identities and pharmacology vary across the vendor market and are usually undisclosed.
Published BMP-mimetic peptides bind type I or type II BMP receptors with reduced affinity relative to full-length BMP proteins, signalling through SMAD1/5/8 phosphorylation to induce osteoblastic differentiation of mesenchymal progenitor cells. Affinity, receptor selectivity, and SMAD-pathway potency vary substantially among published peptides; the vendor-sold 'osteogenic peptide' label rarely identifies which one.
Tier 3 for the class. Multiple published synthetic BMP-mimetic peptides (e.g. P28 and P24 from BMP-2 knuckle epitopes) have rodent osteogenesis data. No FDA-approved BMP-mimetic peptide; the approved bone-morphogenetic-protein products (Infuse rhBMP-2, OP-1 rhBMP-7) are full recombinant proteins, not peptide mimetics.
No human safety database for any vendor 'osteogenic peptide'. Class-level BMP concerns (heterotopic ossification, immunogenicity) apply by extension.
Regulatory status
- FDA status:
- Not FDA-approved
The vendor-sold material cannot be presumed to match the published BMP-mimetic peptides on which the preclinical evidence rests. Without independent identity testing, the buyer is purchasing a label, not a defined chemical entity.